# A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

> **NCT05026905** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 66 (estimated)

## Conditions studied

- Phase II, Open-label, Parallel 2-arm, Multi-center

## Interventions

- **DRUG:** Gemcitabine 1000 mg
- **DRUG:** Nab paclitaxel
- **DRUG:** S1
- **DRUG:** leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05026905
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-28
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026905, "A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05026905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*